Department of Radiology, University of Washington, Seattle, Washington 98195, USA.
J Magn Reson Imaging. 2013 Jun;37(6):1476-9. doi: 10.1002/jmri.23879. Epub 2012 Oct 23.
Ferumoxytol is an iron-containing parenteral treatment for iron deficiency anemia that was recently approved by the Food and Drug Administration. The iron is in the form of a superparamagnetic iron oxide that causes T1, T2, and T2* shortening on magnetic resonance imaging (MRI). Furthermore, the drug has a long intravascular half-life of 14-15 hours; a standard dose can affect MRI for days to months. We describe a case in which a patient underwent contrast-enhanced MRI of the liver 2 days after receiving a dose of ferumoxytol, which was unknown to the radiology team. The blood pool and soft tissues were hyperintense on T1-weighted images, concealing enhancement from the gadolinium-based contrast agent that was administered during the exam and rendering the exam nondiagnostic. Radiologists must be aware of this potential effect in screening patients for MRI and interpreting exams.
Ferumoxytol 是一种含铁的肠外治疗药物，用于治疗缺铁性贫血，最近获得了美国食品和药物管理局的批准。该药物中的铁以超顺磁性氧化铁的形式存在，在磁共振成像（MRI）上会导致 T1、T2 和 T2*缩短。此外，该药物具有 14-15 小时的长血管半衰期；标准剂量可影响 MRI 数天至数月。我们描述了一例患者在接受 ferumoxytol 剂量后 2 天进行肝脏对比增强 MRI 的情况，放射科团队并不知道这一点。血池和软组织在 T1 加权图像上呈高信号，掩盖了在检查期间给予的钆基造影剂的增强，使检查无法诊断。放射科医生在对患者进行 MRI 筛查和解释检查时必须意识到这种潜在的影响。
